The Challenges of Tumor Mutational Burden as an Immunotherapy Biomarker

Denis L. Jardim; Aaron M. Goodman; Débora De Melo Gagliato; Razelle Kurzrock

doi:10.1016/j.ccell.2020.10.001

Keywords

ImmunotherapyBiomarkerComputational biologyBiologyCancer researchMedicineImmunologyGeneticsImmune system

Affiliated Institutions

Related Publications

Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden

Matthew D. Hellmann , Tudor‐Eliade Ciuleanu , Adam Płużański +21 more

Progression-free survival was significantly longer with first-line nivolumab plus ipilimumab than with chemotherapy among patients with NSCLC and a high tumor mutational burden,...

2018 New England Journal of Medicine 3061 citations

Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic

Timothy A. Chan , Mark Yarchoan , Elizabeth M. Jaffee +4 more

Abstract Background Treatment with immune checkpoint blockade (ICB) with agents such as anti-programmed cell death protein 1 (PD-1), anti-programmed death-ligand 1 (PD-L1), and/...

2018 Annals of Oncology 2769 citations

Immune checkpoint signaling and cancer immunotherapy

Xing He , Chenqi Xu

Abstract Immune checkpoint blockade therapy has become a major weapon in fighting cancer. Antibody drugs, such as anti-PD-1 and anti-PD-L1, demonstrate obvious advantages such a...

2020 Cell Research 1257 citations

Pan-tumor genomic biomarkers for PD-1 checkpoint blockade–based immunotherapy

Răzvan Cristescu , Robin Mogg , Mark Ayers +21 more

Mining immunotherapy clinical trials Clinical trial data can provide a wealth of information about how drugs work. Yet such information often belongs to pharmaceutical companies...

2018 Science 2202 citations

Exomics and immunogenics

Stéphane Champiat , Charles Ferté , Sophie Lebel‐Binay +2 more

Anti-PD-1/PD-L1 antibodies are emerging as promising anticancer therapeutics. Interestingly, elevated response rates to these agents are mostly documented among patients with tu...

2014 OncoImmunology 187 citations

Publication Info

Year: 2020
Type: review
Volume: 39
Issue: 2
Pages: 154-173
Citations: 1114
Access: Closed

External Links

View on DOI.org

Social Impact

Altmetric

The Challenges of Tumor Mutational Burden as an Immunotherapy Biomarker

PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

1114

OpenAlex

Cite This

APA Style

                            
                                
                                    Denis L. Jardim, 
                                
                                    Aaron M. Goodman, 
                                
                                    Débora De Melo Gagliato
                                
                                et al.
                            
                            (2020). 
                            The Challenges of Tumor Mutational Burden as an Immunotherapy Biomarker. 
                            Cancer Cell
                            , 39
                            (2)
                            , 154-173.
                            https://doi.org/10.1016/j.ccell.2020.10.001
                        

Identifiers

DOI: 10.1016/j.ccell.2020.10.001